Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private PlacementsGlobeNewsWire • 2h
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024GlobeNewsWire • Monday
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) ConferenceGlobeNewsWire • 09/09/24
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24
Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain StockZacks Investment Research • 09/02/24
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/13/24
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/12/24
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate UpdatesGlobeNewsWire • 08/12/24
Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024GlobeNewsWire • 08/06/24
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027GlobeNewsWire • 07/25/24
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell CarcinomaGlobeNewsWire • 07/25/24
Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO)Zacks Investment Research • 07/15/24
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred StockGlobeNewsWire • 07/05/24
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 07/02/24
Checkpoint Therapeutics Announces Biologics License Application Resubmission for CosibelimabGlobeNewsWire • 07/02/24
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA ResubmissionGlobeNewsWire • 06/24/24
Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company ShowcaseGlobeNewsWire • 05/16/24
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/15/24
Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company ShowcaseGlobeNewsWire • 05/15/24
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver TransplantationGlobeNewsWire • 05/14/24